1. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
   Oscar Arrieta et al, 2020, JAMA Oncology CrossRef
2. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
   Kai He et al, 2023, Journal of Thoracic Oncology CrossRef
3. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
   Barbara A Conley et al, 2021, JNCI: Journal of the National Cancer Institute CrossRef
4. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer
   Keke Nie et al, 2018, Lung Cancer CrossRef
5. Lung Adenocarcinoma
   Bhavisha A. Patel et al, 2019, Pulmonary Adenocarcinoma: Approaches to Treatment CrossRef
6. Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors
   Elena Poddubskaya et al, 2019, Frontiers in Oncology CrossRef